The MIT-Harvard Center for Cancer Nanotechnology Excellence is a collaborative effort among MIT, Harvard University, Harvard Medical School, Massachusetts General Hospital, and Brigham and Women's Hospital. It is one of eight Centers of Cancer Nanotechnology Excellence awarded by The National Cancer Institute (NCI), part of the National Institutes of Health (NIH). It focuses on developing a diversified portfolio of nanoscale devices for targeted delivery of cancer therapies, diagnostics, non-invasive imaging, and molecular sensing. In addition to general oncology applications, the Consortium focuses on prostate, brain, lung, ovarian, and colon cancer.
Examples of projects that the Consortium is undertaking include the development of:
In addition to drawing on the scientific and technological expertise of its investigators, the Consortium uses available facilities for toxicology testing and the extensive mouse models of cancer collection at the collaborating institutions.
Project and Core Abstracts are available online:
NCI Alliance for Nanotechnology in Cancer, MIT-Harvard CCNE
Monthly Presentations for CCNE members (password protected):
CMIR Nanotechnology Program
Robert Langer, Ph.D.
Institute Professor, Massachusetts Institute of Technology
Ralph Weissleder, M.D., Ph.D.
Professor, Harvard Medical School
Director, Center for Systems Biology
Harvard University, Massachusetts General Hospital